WASHINGTON (Sputnik) — Under the FDA’s expanded access program, patients with serious or life threatening ailments and no other comparable medical options can obtain access to investigational drugs outside of a clinical trial, the report noted.. Expanded access requests must be submitted to the agency, the GAO said.
"Of the nearly 5,800 expanded access requests that were submitted to FDA from fiscal year 2012 through 2015, FDA allowed 99 percent to proceed," the report said on Tuesday.
However, some of drugs manufacturers told GAO the FDA’s guidance was unclear and they expressed concern that an adverse event would result in the agency placing a clinical hold on their drug, which could delay its development, the report noted.